Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease (ESRD)
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Trial Timeline
Dec 3, 2013 → Jan 17, 2018
NCT ID
NCT01950819About Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI
Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI is a approved stage product being developed by Novartis for End Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT01950819. Target conditions include End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis.
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease (ESRD) were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01950819 | Approved | Completed |
Competing Products
20 competing products in End Stage Renal Disease (ESRD)